How does 290A's PB Ratio compare to its peers?

290A is expensive based on its Price-To-Book Ratio (8.1x) compared to the peer average (4.9x).

How does 290A's PB Ratio compare vs other companies in the DE Biotechs Industry?

290A is expensive based on its Price-To-Book Ratio (8.1x) compared to the European Biotechs industry average (2.4x)

What is 290A's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 290A's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 290A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 290A's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is lower than the current share price.

Chinook Therapeutics (DB:290A) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

290A Stock Overview

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. More details

290A fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 63.8% per year

Risk Analysis

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Chinook Therapeutics, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€827.2m

MorphoSys

XTRA:MOR

€2.5b

Heidelberg Pharma

XTRA:HPHA

€103.9m

Price History & Performance

Summary of all time highs, changes and price drops for Chinook Therapeutics
Historical stock prices
Current Share Price	US$36.40
52 Week High	US$37.40
52 Week Low	US$16.80
Beta	0.67
11 Month Change	3.41%
3 Month Change	75.00%
1 Year Change	89.58%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	197.82%

Recent updates

Shareholder Returns

	290A	DE Biotechs	DE Market
7D	0.6%	-0.7%	-0.02%
1Y	89.6%	-17.2%	8.2%

Return vs Industry: 290A exceeded the German Biotechs industry which returned -7.5% over the past year.

Return vs Market: 290A exceeded the German Market which returned 1.6% over the past year.

Price Volatility

Is 290A's price volatile compared to industry and market?
290A volatility
290A Average Weekly Movement	20.0%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 290A's share price has been volatile over the past 3 months.

Volatility Over Time: 290A's weekly volatility has increased from 11% to 20% over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	214	Eric Dobmeier	www.chinooktx.com

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company’s lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases.

Chinook Therapeutics, Inc. Fundamentals Summary

How do Chinook Therapeutics's earnings and revenue compare to its market cap?
290A fundamental statistics
Market cap	€2.65b
Earnings (TTM)	-€224.40m
Revenue (TTM)	€5.34m

495.8x

P/S Ratio

-11.8x

P/E Ratio

Is 290A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
290A income statement (TTM)
Revenue	US$5.85m
Cost of Revenue	US$193.72m
Gross Profit	-US$187.87m
Other Expenses	US$57.79m
Earnings	-US$245.65m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-3.42
Gross Margin	-3,211.95%
Net Profit Margin	-4,199.93%
Debt/Equity Ratio	0%

How did 290A perform over the long term?

See historical performance and comparison

This company listing is no longer active

290A Stock Overview

Rewards

Risk Analysis

Chinook Therapeutics, Inc. Competitors

XTRA:BIO3

€1.4b

XTRA:FYB

€827.2m

XTRA:MOR

€2.5b

XTRA:HPHA

€103.9m

Price History & Performance

Recent News & Updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

First quarter 2023 earnings released: US$0.85 loss per share (vs US$0.54 loss in 1Q 2022)

Independent Lead Director recently sold €5.6m worth of stock

Full year 2022 earnings released: US$2.87 loss per share (vs US$2.26 loss in FY 2021)

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

President recently sold €175k worth of stock

Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.69 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.69 loss in 3Q 2021)

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Independent Director recently bought €212k worth of stock

Second quarter 2022 earnings released: US$0.61 loss per share (vs US$0.97 loss in 2Q 2021)

High number of new directors

President recently bought €61k worth of stock

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

First quarter 2022 earnings released: US$0.54 loss per share (vs US$0.88 loss in 1Q 2021)

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

President recently bought €101k worth of stock

Sairopa B.V., entered into an agreement to acquire non-renal assets of Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell Microcap Growth Index

Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress

Chinook Therapeutics, Inc. announced delayed annual 10-K filing

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 Align Study of Atrasentan for Patients with Iga Nephropathy

Chinook Therapeutics, Inc. and Evotec SE Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Chk-336 for Treatment of Primary Hyperoxaluria

Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities

President recently bought €53k worth of stock

Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer

Chinook Therapeutics, Inc. Provides Business Update

Shareholder Returns

Price Volatility

About the Company

Chinook Therapeutics, Inc. Fundamentals Summary

495.8x

-11.8x

Earnings & Revenue